LSBCF (LakeShore Biopharma Co) Net Change in Cash: $-1.85 Mil (TTM As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is LakeShore Biopharma Co Net Change in Cash?

LakeShore Biopharma Co LSBCF Net Change in Cash is $-1.85 Mil as of Mar. 2025.

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

LakeShore Biopharma Co's Net Change in Cash for the six months ended in Mar. 2025 was $0.00 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 was $-1.85 Mil.

LakeShore Biopharma Co Net Change in Cash Historical Data

* Premium members only.

The historical data trend for LakeShore Biopharma Co's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co Net Change in Cash Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Net Change in Cash
59.66 -18.82 14.41 -17.19 -19.18

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Net Change in Cash Get a 7-Day Free Trial Premium Member Only 20.80 -15.14 -1.85 0.00 0.00

LakeShore Biopharma Co Net Change in Cash Calculation

LakeShore Biopharma Co's Net Change in Cash for the fiscal year that ended in Mar. 2025 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-16.689+-2.346+-0.494+0.345
=-19.18

LakeShore Biopharma Co's Net Change in Cash for the quarter that ended in Mar. 2025

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=0+0+0+0
=0.00

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-1.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Change in Cash →
What does a Net Change in Cash of $-1.85 Mil mean?
LakeShore Biopharma Co (LSBCF) has a Net Change in Cash of $-1.85 Mil as of Mar. 2025. The net change in cash is the total change in cash and equivalents between the current period and the past period. View historical data for LakeShore Biopharma Co and its competitors.
Is LakeShore Biopharma Co's Net Change in Cash too high?
LakeShore Biopharma Co's current Net Change in Cash is $-1.85 Mil.
How does LakeShore Biopharma Co's Net Change in Cash compare to ACUT and PPCB?
LakeShore Biopharma Co's Net Change in Cash of $-1.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Change in Cash for a Biotechnology company?
A good Net Change in Cash depends on the Biotechnology industry context. However, Net Change in Cash should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Change in Cash mean?
A high Net Change in Cash can signal that a stock is expensive relative to its fundamentals. The net change in cash is the total change in cash and equivalents between the current period and the past period. View historical data for LakeShore Biopharma Co and its competitors. LakeShore Biopharma Co's current Net Change in Cash is $-1.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current Net Change in Cash of $-1.85 Mil. The current Net Change in Cash is $-1.85 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Change in Cash calculated?
Net Change in Cash is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current Net Change in Cash is $-1.85 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LakeShore Biopharma Co Business Description

Address 38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.